Late cardiotoxicity following anthracycline therapy for childhood cancer
Key result
Late clinical cardiotoxicity occurs in 5-10% of long-term childhood cancer survivors 5-10 years after anthracycline therapy, with cumulative dose, younger age, and female sex as risk factors.
Why the study?
What is the frequency, severity, and risk factors of late cardiotoxicity following anthracycline therapy for childhood cancer?
Population
Childhood cancer survivors who received anthracycline therapy
Design
Review
Follow-up
5-10 years and beyond
Authors
Discussion
Loading...
Member takes
Implication
Long-term survivors warrant serial cardiac evaluation; leaves open optimal screening and intervention strategies.
Structured PICO
What is the frequency, severity, and risk factors of late cardiotoxicity following anthracycline therapy for childhood cancer?
P
Population
Review of studies assessing cardiac function in childhood cancer survivors more than 1 year after cessation of anthracycline therapy.
E
Exposure
Anthracycline therapy
O
Outcome
Late cardiotoxicity (clinical and subclinical) more than 1 year after cessation of therapysafety
Late cardiotoxicity is a frequent, potentially severe complication in childhood cancer survivors treated with anthracyclines, highlighting the need for long-term monitoring.
Limitations
- Considerable controversy exists on the frequency, severity and risk factors of late subclinical cardiotoxicity
- Unknown whether late cardiotoxicity will significantly reduce long-term survival or impair quality of life during the second and third decades
Cite This Study
Nysom et al. (1998) conducted a review in Childhood cancer. Anthracycline therapy was evaluated on Late clinical cardiotoxicity. Late clinical cardiotoxicity occurs in 5-10% of long-term childhood cancer survivors 5-10 years after anthracycline therapy, with cumulative dose, younger age, and female sex as risk factors.